Structure, expression and function of HLA-G in renal cell carcinoma

Seminars in Cancer Biology

Volumn 17, Issue 6, 2007, Pages 444-450

  Seliger, Barbara ^a   Schlaf, Gerald ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Classical HLA antigens; HLA G; Immune escape; Immune response; Kidney tumor

Indexed keywords

CD8 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA G ANTIGEN; MESSENGER RNA;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; CANCER CHEMOTHERAPY; CELL FUNCTION; CELL INFILTRATION; CELL TYPE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; LYMPHOKINE ACTIVATED KILLER CELL; METHYLATION; NATURAL KILLER CELL; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

CARCINOMA, RENAL CELL; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; KIDNEY NEOPLASMS; POLYMORPHISM, GENETIC; TUMOR ESCAPE;

EID: 35748951881     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2007.07.001     Document Type: Review

References (75)

1. Mostofi F.K., and Daves C.J. Histological typing of kidney tumors (1998), WHO Springer, Berlin
2. Gnarra J.R., Lerman M.I., Zbar B., and Linehan W.M. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22 (1995) 3-8
3. Alexandrescu D.T., and Dasanu C.A. Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother 7 (2006) 2481-2493
4. Yang J.C., and Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 24 (2006) 5576-5583
5. Motzer R.J., and Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 5601-5608
6. Finke J.H., Rayman P., Edinger M., Tubbs R.R., Stanley J., Klein E., et al. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 11 (1992) 1-11
7. Brouwenstijn N., Gaugler B., Kruse K.M., van der Spek C.W., Mulder A., Osanto S., et al. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int J Cancer 68 (1996) 177-182
8. Gaudin C., Kremer F., Angevin E., Scott V., and Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 162 (1999) 1730-1738
9. Guerra N., Guillard M., Angevin E., Echchakir H., Escudier B., Moretta A., et al. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood 95 (2000) 2883-2889
10. Algarra I., Garcia-Lora A., Cabrera T., Ruiz-Cabello F., and Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53 (2004) 904-910
11. Seliger B. Strategies of tumor immune evasion. BioDrugs 19 (2005) 347-354
12. Seliger B., Abken H., and Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 24 (2003) 82-87
13. Atkins D., Ferrone S., Schmahl G.E., Storkel S., and Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J Urol 171 (2004) 885-889
14. Seliger B., Atkins D., Bock M., Ritz U., Ferrone S., Huber C., et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing downregulation. Clin Cancer Res 9 (2003) 1721-1727
15. Seliger B., Hohne A., Knuth A., Bernhard H., Meyer T., Tampe R., et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56 (1996) 1756-1760
16. Hodson I., Bock M., Ritz U., Brenner W., Huber C., and Seliger B. Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma. Int J Oncol 23 (2003) 991-999
17. Seliger B., Bock M., Ritz U., and Huber C. High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors. Int J Oncol 20 (2002) 349-353
18. Seliger B., Hohne A., Knuth A., Bernhard H., Ehring B., Tampe R., et al. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 2 (1996) 1427-1433
19. Lahn M., Fisch P., Kohler G., Kunzmann R., Hentrich I., Jesuiter H., et al. Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. Eur Urol 35 (1999) 70-80
20. Nakagomi H., Pisa P., Pisa E.K., Yamamoto Y., Halapi E., Backlin K., et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 63 (1995) 366-371
21. Biswas K., Richmond A., Rayman P., Biswas S., Thornton M., Sa G., et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 66 (2006) 6816-6825
22. Finke J.H., Rayman P., George R., Tannenbaum C.S., Kolenko V., Uzzo R., et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. Clin Cancer Res 7 (2001) 940s-946s
23. Finke J.H., Zea A.H., Stanley J., Longo D.L., Mizoguchi H., Tubbs R.R., et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53 (1993) 5613-5616
24. Bukowski R.M., Rayman P., Uzzo R., Bloom T., Sandstrom K., Peereboom D., et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 4 (1998) 2337-2347
25. Uzzo R.G., Kolenko V., Froelich C.J., Tannenbaum C., Molto L., Novick A.C., et al. The T cell death knell: immune-mediated tumor death in renal cell carcinoma. Clin Cancer Res 7 (2001) 3276-3281
26. Jung D., Hilmes C., Knuth A., Jaeger E., Huber C., and Seliger B. Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 50 (1999) 242-249
27. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M., et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci 103 (2006) 10391-10396
28. Thompson R.H., Kuntz S.M., Leibovich B.C., Dong H., Lohse C.M., Webster W.S., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66 (2006) 3381-3385
29. Thompson R.H., Dong H., and Kwon E.D. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 13 (2007) 709s-715s
30. Thompson R.H., Dong H., Lohse C.M., Leibovich B.C., Blute M.L., Cheville J.C., et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13 (2007) 1757-1761
31. Carosella E.D., Rouas-Freiss N., Paul P., and Dausset J. HLA-G: a tolerance molecule from the major histocompatibility complex. Immunol Today 20 (1999) 60-62
32. Ishitani A., and Geraghty D.E. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 89 (1992) 3947-3951
33. Horuzsko A., Protik-Dobos V., Hansen K.A., Markowitz R.B., Helman S.W., and Mellor A.L. Induction of HLA-G-specific human CD8+ T cell lines by stimulation across a polymorphism of HLA-G. Transplant Proc 31 (1999) 1860-1863
34. Cantoni C., Verdiani S., Falco M., Pessino A., Cilli M., Conte R., et al. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. Eur J Immunol 28 (1998) 1980-1990
35. Rajagopalan S., and Long E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 189 (1999) 1093-1100
36. Ponte M., Cantoni C., Biassoni R., Tradori-Cappai A., Bentivoglio G., Vitale C., et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci 96 (1999) 5674-5679
37. Yan W.H., and Fan L.A. Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition. Cell Res 15 (2005) 176-182
38. Bahri R., Hirsch F., Josse A., Rouas-Freiss N., Bidere N., Vasquez A., et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 176 (2006) 1331-1339
39. LeMaoult J., Zafaranloo K., Le Danff C., and Carosella E.D. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19 (2005) 662-664
40. Favier B., LeMaoult J., Rouas-Freiss N., Noreau P., Menier C., and Carosella E.D. Research on HLA-G: an update. Tissue Antigens 69 (2007) 207-211
41. Rouas-Freiss N., Moreau P., Ferrone S., and Carosella E.D. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res 65 (2005) 10139-10144
42. Tripathi P., and Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest 24 (2006) 178-186
43. Polakova K., Krcova M., Kuba D., and Russ G. Analysis of HLA-G expression in malignant hematopoetic cells from leukaemia patients. Leuk Res 27 (2003) 643-648
44. Urosevic M., Willers J., Mueller B., Kempf W., Burg G., and Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99 (2002) 609-617
45. Davies B., Hiby S., Gardner L., Loke Y.W., and King A. HLA-G expression by tumors. Am J Reprod Immunol 45 (2001) 103-107
46. Paul P., Cabestre F.A., Le Gal F.A., Khalil-Daher I., Le Danff C., Schmid M., et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 59 (1999) 1954-1960
47. Real L.M., Cabrera T., Collado A., Jimenez P., Garcia A., Ruiz-Cabello F., et al. Expression of HLA G in human tumors is not a frequent event. Int J Cancer 81 (1999) 512-518
48. Menier C., Saez B., Horejsi V., Martinozzi S., Krawice-Radanne I., Bruel S., et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 64 (2003) 315-326
49. Ibrahim E.C., Allory Y., Commo F., Gattegno B., Callard P., and Paul P. Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. Am J Pathol 162 (2003) 501-508
50. Ibrahim E.C., Guerra N., Lacombe M.J., Angevin E., Chouaib S., Carosella E.D., et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61 (2001) 6838-6845
51. Bukur J., Rebmann V., Grosse-Wilde H., Luboldt H., Ruebben H., Drexler I., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63 (2003) 4107-4111
52. Bukur J., and Seliger B. The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. Semin Cancer Biol 13 (2003) 353-359
53. Ye S.R., Yang H., Li K., Dong D.D., Lin X.M., and Yie S.M. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 20 (2007) 375-383
54. Moreau P., Adrian-Cabestre F., Menier C., Guiard V., Gourand L., Dausset J., et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 11 (1999) 803-811
55. Bamberger A.M., Jenatschke S., Schulte H.M., Loning T., and Bamberger M.C. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab 85 (2000) 3932-3936
56. Kilburn B.A., Wang J., Duniec-Dmuchowski Z.M., Leach R.E., Romero R., and Armant D.R. Extracellular matrix composition and hypoxia regulate the expression of HLA-G and integrins in a human trophoblast cell line. Biol Reprod 62 (2000) 739-747
57. Mouillot G., Marcou C., Zidi I., Guillard C., Sangrouber D., Carosella E.D., et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 68 (2007) 277-285
58. Shido F., Ito T., Nomura S., Yamamoto E., Sumigama S., Ino K., et al. Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells. Endocrinology 147 (2006) 1780-1788
59. Moreau P., Faure O., Lefebvre S., Ibrahim E.C., O'Brien M., Gourand L., et al. Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. Transplant Proc 33 (2001) 2277-2280
60. Yang Y., Chu W., Geraghty D.E., and Hunt J.S. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol 156 (1996) 4224-4231
61. Rousseau P., Masternak K., Krawczyk M., Reith W., Dausset J., Carosella E.D., et al. In vivo, RFX5 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner. Immunology 111 (2004) 53-65
62. Schmidt C.M., Ehlenfeldt R.G., Athanasiou M.C., Duvick L.A., Heinrichs H., David C.S., et al. Extraembryonic expression of the human MHC class I gene HLA-G in transgenic mice. Evidence for a positive regulatory region located 1 kilobase 5′ to the start site of transcription. J Immunol 151 (1993) 2633-2645
63. Lefebvre S., Berrih-Aknin S., Adrian F., Moreau P., Poea S., Gourand L., et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem 276 (2001) 6133-6139
64. Mouillot G., Marcou C., Rousseau P., Rouas-Freiss N., Carosella E.D., and Moreau P. HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int J Cancer 113 (2005) 928-936
65. Yan W.H., Lin A.F., Chang C.C., and Ferrone S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2′-deoxycytidine. Cell Res 15 (2005) 523-531
66. Moreau P., Mouillot G., Rousseau P., Marcou C., Dausset J., and Carosella E.D. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci 100 (2003) 1191-1196
67. Pyo C.W., Williams L.M., Moore Y., Hyodo H., Li S.S., Zhao L.P., et al. HLA-E, HLA-F, and HLA-G polymorphism: genomic sequence defines I genes. Immunogenetics 58 (2006) 241-251
68. Harrison G.A., Humphrey K.E., Jakobsen I.B., and Cooper D.W. A 14-bp deletion polymorphism in the HLA-G gene. Hum Mol Genet 2 (1993) 2200
69. Ober C., Aldrich C.L., Chervoneva I., Billstrand C., Rahimov F., Gray H.L., et al. Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet 72 (2003) 1425-1435
70. Glas J., Torok H.P., Tonenchi L., Wetzke M., Beynon V., Teshome M.Y., et al. The 14-bp deletion polymorphism in the HLA-G gene displays significant differences between ulcerative colitis and Crohn's disease and is associated with ileocecal resection in Crohn's disease. Int Immunol 19 (2007) 621-626
71. Hara N., Fujii T., Yamashita T., Kozuma S., Okai T., and Taketani Y. Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: immunohistological demonstration with anti-HLA-G specific antibody 87G and anti-cytokeratin antibody CAM5.2. Am J Reprod Immunol 36 (1996) 349-358
72. Mendes-Junior C.T., Castelli E.C., Simões R.T., Simões A.L., and Donadi E.A. HLA-G 14-bp polymorphism at exon 8 in Amerindian populations from the Brazilian Amazon. Tissue Antigens 69 (2007) 255-260
73. Rouas-Freiss N., Bruel S., Menier C., Marcou C., Moreau P., and Carosella E.D. Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int J Cancer 117 (2005) 114-122
74. Favier B., LeMaoult J., and Carosella E.D. Functions of HLA-G in the immune system. Tissue Antigens 69 (2007) 150-152
75. Bukur J., Malenica B., Huber C., and Seliger B. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol 64 (2003) 1081-1092